PMID- 32382302
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220414
IS  - 1741-427X (Print)
IS  - 1741-4288 (Electronic)
IS  - 1741-427X (Linking)
VI  - 2020
DP  - 2020
TI  - Traditional Chinese Patent Medicine for Primary Hypertension: A Bayesian Network 
      Meta-Analysis.
PG  - 6701272
LID - 10.1155/2020/6701272 [doi]
LID - 6701272
AB  - BACKGROUND: Traditional Chinese Patent Medicine (TCPM) is now being used more and 
      more extensively for primary hypertension in China. However, the comparative 
      efficacy and safety of it need more clarified evidence. Thus, we conducted a 
      Bayesian network meta-analysis to compare TCPMs with other interventions. 
      METHODS: We searched China National Knowledge Infrastructure (CNKI), WanFang 
      Data, PubMed, Embase, and Cochrane Library from inception to April 2019 for 
      randomized controlled trials (RCTs) with diagnosis of primary hypertension that 
      compared the efficacy of TCPMs with antihypertension drugs (ADs). Two researchers 
      screened literature, extracted data, and evaluated risk of bias independently. 
      The primary outcomes were systolic blood pressure (SBP) and diastolic blood 
      pressure (DBP). The secondary outcomes were adverse effects (AEs), total 
      cholesterol (TC), and triglyceride (TG). We used the Bayesian network 
      meta-analysis to compare interventions and described the categorical variable and 
      the continuous variable as odds ratio (OR) and mean difference (MD), 
      respectively. Besides, we ranked all interventions via the Surface Under the 
      Cumulative Ranking (SUCRA) values and conducted metaregression with nine 
      covariates as additional analysis. RESULTS: We included 192 studies with 23366 
      patients diagnosed as primary hypertension in total. For SBP reduction, eighteen 
      interventions were significantly better than AD. Among them, Yinxingye (YXY) + AD 
      (MD = -12, 95% CrI [-16, -8.5]) was superior to others in the rank plot with 
      SUCRA 0.91. For DBP reduction, sixteen interventions were significantly better 
      than AD. Among them, Qinggan Jiangya (QGJY) + AD (MD = -8.7, 95% CrI [-12, -5.5]) 
      and Qiju Dihuang (QJDH) + AD (MD = -8.8, 95% CrI [-12, -5.2]) were superior to 
      others in the rank plot with SUCRA 0.89. To summarize the SUCRA values, we found 
      that QGJY + AD and YXY + AD had the most significant reductions for both SBP and 
      DBP. YXY + AD was the best one for both TC (MD = -1.3, 95% CrI [-1.9, -0.64]) and 
      TG (MD = -0.52, 95% CrI [-0.92, -0.11]) reductions. Considering adverse effects, 
      we found two interventions had significant differences comparing with AD. Among 
      them, YXY + AD was the best one with SUCRA of 0.01. CONCLUSION: In all TCPMs, 
      QGJY + AD and YXY + AD may be the best options for hypertension. Meanwhile, 
      YXY + AD can improve blood lipids in patients with hypertension. However, due to 
      the vague reports of adverse effects and other limitations, more evidence, 
      especially that provided by high-quality studies, is needed to prove the 
      advantages of TCMPs.
CI  - Copyright (c) 2020 Zhe Chen et al.
FAU - Chen, Zhe
AU  - Chen Z
AUID- ORCID: 0000-0001-6977-570X
AD  - Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China.
FAU - Shi, Qingyang
AU  - Shi Q
AUID- ORCID: 0000-0002-4887-6410
AD  - Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China.
FAU - Tan, Lizi
AU  - Tan L
AUID- ORCID: 0000-0001-8263-5904
AD  - Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China.
FAU - Peng, Yingying
AU  - Peng Y
AUID- ORCID: 0000-0003-4611-0873
AD  - Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China.
FAU - Liu, Chunxiang
AU  - Liu C
AUID- ORCID: 0000-0003-4063-3729
AD  - Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China.
AD  - Evidence-based Medicine Center, Tianjin University of Traditional Chinese 
      Medicine, Tianjin 301617, China.
FAU - Zhang, Junhua
AU  - Zhang J
AUID- ORCID: 0000-0003-4043-1967
AD  - Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China.
AD  - Evidence-based Medicine Center, Tianjin University of Traditional Chinese 
      Medicine, Tianjin 301617, China.
LA  - eng
PT  - Journal Article
DEP - 20200424
PL  - United States
TA  - Evid Based Complement Alternat Med
JT  - Evidence-based complementary and alternative medicine : eCAM
JID - 101215021
PMC - PMC7196995
COIS- The authors declare that there are no conflicts of interest.
EDAT- 2020/05/10 06:00
MHDA- 2020/05/10 06:01
PMCR- 2020/04/24
CRDT- 2020/05/09 06:00
PHST- 2019/07/30 00:00 [received]
PHST- 2020/03/16 00:00 [accepted]
PHST- 2020/05/09 06:00 [entrez]
PHST- 2020/05/10 06:00 [pubmed]
PHST- 2020/05/10 06:01 [medline]
PHST- 2020/04/24 00:00 [pmc-release]
AID - 10.1155/2020/6701272 [doi]
PST - epublish
SO  - Evid Based Complement Alternat Med. 2020 Apr 24;2020:6701272. doi: 
      10.1155/2020/6701272. eCollection 2020.